Latest Hotspot

AriBio Gains IND Approval from China's NMPA for Phase 3 Alzheimer's Trial, POLARIS-AD

17 May 2024
3 min read

AriBio Co., Ltd., a biotechnology firm focused on developing innovative therapies for neurodegenerative conditions, has revealed the approval of their Investigational New Drug application by the Center for Drug Evaluation of China's National Medical Products Administration. This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The Phase 3 clinical trial will recruit early Alzheimer's Disease (AD) patients at up to 20 trial centers in China, with consistent eligibility criteria as in other participating countries. Key evaluation metrics include the Clinical Dementia Rating Scale  Sum of Boxes, Alzheimer’s Disease Assessment Scale-Cognitive Subscale, Amsterdam-Activities of Daily Living Questionnaire, Geriatric Depression Scale, Mini-Mental State Examination, and changes in cerebrospinal fluid, imaging, and plasma biomarkers.

After the successful acceptance of the POLARIS-AD Investigational New Drug (IND) and clinical trial applications in 11 countries, such as the United States, Korea, United Kingdom, Germany, France, Spain, Italy, Denmark, Netherlands, the Czech Republic, and now China, AriBio demonstrates its global dedication to developing innovative therapies for Alzheimer's disease.

Including China, a key player in the international pharmaceutical market, in the Phase 3 development of AR1001 allows AriBio to further enhance its influence in combating Alzheimer's disease. This trial aims to enroll approximately 1,150 participants across over 200 clinical centers in 11 countries.

AriBio’s CEO, Dr. Jai Jun Choung, expressed his enthusiasm for this milestone, stating, “We are elated to receive the IND approval for AR1001 in China. This major milestone underscores AriBio’s relentless effort to advance pioneering treatments for Alzheimer’s disease on a global stage. With IND approval now secured in all our targeted countries, including China, we are closer to offering hope to millions of patients globally.”

Looking ahead, AriBio plans to commence the Phase 3 clinical trial in China in the third quarter of 2024. Dr. Choung emphasized AriBio’s commitment to success, noting, “As the first Korean biopharmaceutical company to directly manage and conduct a global Phase 3 clinical trial of this magnitude, we approach our mission with pride and responsibility. We appreciate the support and attention from all participating countries and continue to pursue groundbreaking treatments for Alzheimer’s disease with unwavering determination.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of May 16, 2024, there are 101 investigational drugs for the PDE5 target, including 106 indications, 143 R&D institutions involved, with related clinical trials reaching 1596, and as many as 5503 patents.

AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, demonstrating multiple mechanisms of action for disease modifying effects that may ameliorate the course of AD.

Mirodenafil dihydrochloride represents a significant advancement in the field of biomedicine, particularly in the treatment of Alzheimer's Disease. Its progression to Phase 3 globally and IND approval in China demonstrates the potential for this small molecule drug to address unmet medical needs in the field of nervous system diseases.

图形用户界面, 文本, 网站

描述已自动生成

Fulcrum Therapeutics and Sanofi Partner on Losmapimod for FSHD Treatment
Latest Hotspot
3 min read
Fulcrum Therapeutics and Sanofi Partner on Losmapimod for FSHD Treatment
17 May 2024
Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.
Read →
Azura Ophthalmics Presents AZR-MD-001 Data as Potential First Keratolytic for Ocular Surface Diseases
Pharma Pioneer
3 min read
Azura Ophthalmics Presents AZR-MD-001 Data as Potential First Keratolytic for Ocular Surface Diseases
17 May 2024
The data reveal that the experimental AZR-MD-001 has shown lasting effects in enhancing the ocular symptoms of Meibomian Gland Dysfunction (MGD) after a six-month treatment period.
Read →
REGENXBIO's Lancet-Published Study Assesses One-Time Gene Therapy ABBV-RGX-314 for Wet AMD
Pharma Pioneer
3 min read
REGENXBIO's Lancet-Published Study Assesses One-Time Gene Therapy ABBV-RGX-314 for Wet AMD
17 May 2024
The innovative gene therapy ABBV-RGX-314 is poised to set a new benchmark in the treatment of wet age-related macular degeneration (AMD).
Read →
Ocean Biomedical JV Partner Virion Therapeutics Presents Encouraging Phase 1B Data for HBV Immunotherapy at APASL
Pharma Pioneer
3 min read
Ocean Biomedical JV Partner Virion Therapeutics Presents Encouraging Phase 1B Data for HBV Immunotherapy at APASL
17 May 2024
Ocean Biomedical has expressed its congratulations to its joint venture (JV) partner, Virion Therapeutics.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.